
SUPN Earnings & Financial Statements
Supernus Pharmaceuticals, Inc.
$28.96
-$0.08(-0.28%)
36
Overall
45
Value
27
Tech
36
Quality
Market Cap
$6.03B
Volume
2.71M
52W Range
$25.92 - $59.68
Target Price
$49.89
SUPN earnings and financial statements: Supernus Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
SUPN Annual Financial Statements
| Fiscal year | 2026 | 2025 | 2025 | 2025 | 2024 |
|---|---|---|---|---|---|
| Revenue | $317.00M | $718.95M | $314.00M | $266.00M | $1.19B |
| Cost of revenue | $40.00M | $74.56M | $83.00M | $44.00M | $231.00M |
| Operating income | $137.00M | -$36.86M | $43.00M | $67.00M | $42.00M |
| EBITDA | $144.00M | $304.00M | $50.00M | $76.00M | $97.00M |
| Net income | $89.00M | -$38.55M | $43.00M | $48.00M | $15.00M |
| EPS (diluted) | $0.69 | $1.64 | $0.33 | $0.38 | $0.05 |
| Fiscal year | 2026 | 2025 | 2025 | 2025 | 2024 |
|---|---|---|---|---|---|
| Total assets | $1.20B | $1.45B | $1.42B | $1.38B | $1.31B |
| Total liabilities | $1.34B | $390.93M | $1.62B | $1.66B | $1.65B |
| Shareholders’ equity | -$144.00M | $1.06B | -$207.00M | -$286.00M | -$327.00M |
| Cash and equivalents | $175.00M | $128.45M | $445.00M | $372.00M | $319.00M |
| Long-term debt | $500.00M | $30.36M | $328.00M | $341.00M | $347.00M |
| Fiscal year | 2026 | 2025 | 2025 | 2025 | 2024 |
|---|---|---|---|---|---|
| Operating cash flow | -$10.00M | $47.33M | $195.00M | $73.00M | $36.00M |
| Capital expenditure | - | -$1.34M | - | - | -$725.0K |
| Free cash flow | -$30.00M | $45.99M | $153.00M | $68.00M | $7.00M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SUPN | $28.96 | -0.3% | 2.71M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Supernus Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW